1.Research progress on the mechanism of sesquiterpenoids against hepatocellular carcinoma
Jingxin MAO ; Xin DU ; Yan LI
China Pharmacy 2025;36(3):379-384
		                        		
		                        			
		                        			As one of the most common solid organ malignant tumors in the world, hepatocellular carcinoma has climbed to the fourth place in incidence rate and the second place in mortality in China, which seriously threatens people’s health. Terpenoids are natural active substances widely present in nature, among which sesquiterpenoids are numerous. They exhibit a variety of pharmacological activities, such as anti-tumor, antibacterial, anti-inflammatory, antiviral and antioxidant activities. This article reviews the research progress on the anti-hepatocellular carcinoma mechanism of sesquiterpenes from 2015 to 2024. The results showed that 24 sesquiterpenoids for the treatment of hepatocellular carcinoma have been reported in the literature in the past 10 years, and these compounds have shown potential in treating hepatocellular carcinoma by inhibiting cancer cell proliferation, inducing apoptosis, preventing invasion and metastasis, regulating immunity, and enhancing anti-drug resistance. The mechanism of anti-hepatocellular carcinoma mainly involves three regulatory pathways: phosphatidylinositol 3-kinase/protein kinase B/ mammalian target of rapamycin signaling pathway, nuclear factor kappa-B signaling pathway, and mitochondrial pathway. In the future, it is necessary to continue to explore new anti-hepatocellular carcinoma drugs with high research value, conduct in-depth analysis on the mechanism of synergistic anti-hepatocellular cancer effects of multiple components, targets, pathways, and accelerate the development of finished products in order to be widely used in clinical practice.
		                        		
		                        		
		                        		
		                        	
2.SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinoma
Yalong DENG ; Lu ZHANG ; Changyuan DAI ; Yan XU ; Qiyu GAN ; Jingxin CHENG
Journal of Gynecologic Oncology 2024;35(6):e79-
		                        		
		                        			 Objective:
		                        			Signaling lymphocytic activation molecule family members (SLAMFs) play a critical role in immune regulation of malignancies. This study aims to investigate the prognostic value and function of SLAMFs in ovarian cancer (OC). 
		                        		
		                        			Methods:
		                        			The expression analysis of SLAMFs was conducted based on The Cancer Genome Atlas Ovarian Cancer Collection (TCGA-OV) and Gene Expression Omnibus (GEO) databases. Immunohistochemistry (IHC) was further performed on tissue arrays (n=98) to determine the expression of SLAMF7. Kaplan-Meier plotter and multivariate Cox regression model were used to evaluate the correlation of SLAMF7 expression with survival outcomes of patients. The molecular function of SLAMF7 in OC was further investigated using Gene Set Enrichment Analysis (GSEA). 
		                        		
		                        			Results:
		                        			SLAMF7 mRNA expression were significantly upregulated in OC tumor tissue compared to normal tissue. IHC revealed that SLAMF7 expression was located in the interstitial parts of tumor tissue, and higher SLAMF7 expression was associated with favorable survival outcomes. GSEA demonstrated that SLAMF7 is involved immune-related pathways. Further analysis showed that SLAMF7 had a strong correlation with the T cellspecific biomarker (CD3) but not with the B cell (CD19, CD22, and CD23) and natural killer cell-specific biomarkers (CD85C, CD336, and CD337). Furthermore, IHC analysis confirmed that SLAMF7 was expressed in tumor-infiltrating T cells, and the IHC score of SLAMF7 was positively correlated with CD3 (r=0.85, p<0.001). 
		                        		
		                        			Conclusion
		                        			SLAMF7 is expressed in the interstitial components of clinical OC tissue, and higher SLAMF7 expression indicated a favorable prognosis for patients with OC.Additionally, SLAMF7 is involved in T-cell immune infiltration in OC. 
		                        		
		                        		
		                        		
		                        	
3.SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinoma
Yalong DENG ; Lu ZHANG ; Changyuan DAI ; Yan XU ; Qiyu GAN ; Jingxin CHENG
Journal of Gynecologic Oncology 2024;35(6):e79-
		                        		
		                        			 Objective:
		                        			Signaling lymphocytic activation molecule family members (SLAMFs) play a critical role in immune regulation of malignancies. This study aims to investigate the prognostic value and function of SLAMFs in ovarian cancer (OC). 
		                        		
		                        			Methods:
		                        			The expression analysis of SLAMFs was conducted based on The Cancer Genome Atlas Ovarian Cancer Collection (TCGA-OV) and Gene Expression Omnibus (GEO) databases. Immunohistochemistry (IHC) was further performed on tissue arrays (n=98) to determine the expression of SLAMF7. Kaplan-Meier plotter and multivariate Cox regression model were used to evaluate the correlation of SLAMF7 expression with survival outcomes of patients. The molecular function of SLAMF7 in OC was further investigated using Gene Set Enrichment Analysis (GSEA). 
		                        		
		                        			Results:
		                        			SLAMF7 mRNA expression were significantly upregulated in OC tumor tissue compared to normal tissue. IHC revealed that SLAMF7 expression was located in the interstitial parts of tumor tissue, and higher SLAMF7 expression was associated with favorable survival outcomes. GSEA demonstrated that SLAMF7 is involved immune-related pathways. Further analysis showed that SLAMF7 had a strong correlation with the T cellspecific biomarker (CD3) but not with the B cell (CD19, CD22, and CD23) and natural killer cell-specific biomarkers (CD85C, CD336, and CD337). Furthermore, IHC analysis confirmed that SLAMF7 was expressed in tumor-infiltrating T cells, and the IHC score of SLAMF7 was positively correlated with CD3 (r=0.85, p<0.001). 
		                        		
		                        			Conclusion
		                        			SLAMF7 is expressed in the interstitial components of clinical OC tissue, and higher SLAMF7 expression indicated a favorable prognosis for patients with OC.Additionally, SLAMF7 is involved in T-cell immune infiltration in OC. 
		                        		
		                        		
		                        		
		                        	
4.SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinoma
Yalong DENG ; Lu ZHANG ; Changyuan DAI ; Yan XU ; Qiyu GAN ; Jingxin CHENG
Journal of Gynecologic Oncology 2024;35(6):e79-
		                        		
		                        			 Objective:
		                        			Signaling lymphocytic activation molecule family members (SLAMFs) play a critical role in immune regulation of malignancies. This study aims to investigate the prognostic value and function of SLAMFs in ovarian cancer (OC). 
		                        		
		                        			Methods:
		                        			The expression analysis of SLAMFs was conducted based on The Cancer Genome Atlas Ovarian Cancer Collection (TCGA-OV) and Gene Expression Omnibus (GEO) databases. Immunohistochemistry (IHC) was further performed on tissue arrays (n=98) to determine the expression of SLAMF7. Kaplan-Meier plotter and multivariate Cox regression model were used to evaluate the correlation of SLAMF7 expression with survival outcomes of patients. The molecular function of SLAMF7 in OC was further investigated using Gene Set Enrichment Analysis (GSEA). 
		                        		
		                        			Results:
		                        			SLAMF7 mRNA expression were significantly upregulated in OC tumor tissue compared to normal tissue. IHC revealed that SLAMF7 expression was located in the interstitial parts of tumor tissue, and higher SLAMF7 expression was associated with favorable survival outcomes. GSEA demonstrated that SLAMF7 is involved immune-related pathways. Further analysis showed that SLAMF7 had a strong correlation with the T cellspecific biomarker (CD3) but not with the B cell (CD19, CD22, and CD23) and natural killer cell-specific biomarkers (CD85C, CD336, and CD337). Furthermore, IHC analysis confirmed that SLAMF7 was expressed in tumor-infiltrating T cells, and the IHC score of SLAMF7 was positively correlated with CD3 (r=0.85, p<0.001). 
		                        		
		                        			Conclusion
		                        			SLAMF7 is expressed in the interstitial components of clinical OC tissue, and higher SLAMF7 expression indicated a favorable prognosis for patients with OC.Additionally, SLAMF7 is involved in T-cell immune infiltration in OC. 
		                        		
		                        		
		                        		
		                        	
5.Effect of Modified Huangqi Guizhi Wuwutang on Stress-related IRE1α/CHOP Pathway of Sciatic Nerve Endoplasmic Reticulum in Diabetes Rats
Yan ZHANG ; Hongzhu LONG ; Xipeng WANG ; Weifang CAO ; Lili WU ; Tonghua LIU ; Jingxin ZHOU
Chinese Journal of Experimental Traditional Medical Formulae 2023;29(16):43-51
		                        		
		                        			
		                        			ObjectiveTo investigate the protective effect of modified Huangqi Guizhi Wuwutang (MHGW) on endoplasmic reticulum stress in the sciatic nerve of diabetes rats based on the pathways of inositol-requiring enzyme 1α (IRE1α) and CCAAT/enhancer-binding protein homologous protein (CHOP). MethodSixty rats were fed on a high-sugar and high-fat diet for six weeks, followed by intraperitoneal injection of streptozotocin at a dose of 35 mg·kg-1. Random blood glucose levels were measured three days later and rats with a sustained blood glucose level ≥ 16.7 mmol·L-1 were included in study (n=48). The rats were randomly divided into a model group, an α-lipoic acid group (0.026 8 g·kg-1·d-1), a high-dose MHGW group (2.5 g·kg-1·d-1), and a low-dose MHGW group (1.25 g·kg-1·d-1). Another 10 rats were assigned to the normal group. The intervention lasted for 16 weeks. After 16 weeks, the sciatic nerve structure of the rats in each group was observed under light microscopy using Luxol fast blue (LFB) staining. Transmission electron microscopy was used to observe the ultrastructure of the sciatic nerve. Chemiluminescence method was employed to measure the serum reactive oxygen species (ROS) levels. Western blot and real-time fluorescence quantitative polymerase chain reaction (Real-time PCR) were used to evaluate the expression of p-IRE1α protein, IRE1α mRNA, CHOP protein, and CHOP mRNA in the sciatic nerve of the rats. ResultCompared with the normal group, the model group showed elevated serum ROS levels (P<0.01). In contrast, the serum ROS levels were significantly reduced in the treatment groups compared with those in the model group (P<0.01). The sciatic nerve of the model group showed pathological changes compared with that in the normal group, while the treatment groups exhibited improvement in sciatic nerve pathology compared with the model group. The protein expression of p-IRE1α and CHOP in the sciatic nerve significantly increased in the model group as compared with that in the normal group (P<0.01). However, the treatment groups showed a significant decrease in the protein expression of p-IRE1α and CHOP in the sciatic nerve compared with the model group (P<0.05, P<0.01). Furthermore, compared with the normal group, the model group showed upregulated mRNA expression of IRE1α and CHOP in the sciatic nerve (P<0.01), while the treatment groups exhibited a significant decrease in the mRNA expression of IRE1α and CHOP compared with the model group (P<0.01). ConclusionMHGW can alleviate endoplasmic reticulum stress-induced cell apoptosis and improve the structure and function of the sciatic nerve in diabetes rats by inhibiting the expression of IRE1α/CHOP pathway-related proteins and mRNA, thereby preventing and treating peripheral neuropathy in diabetes. 
		                        		
		                        		
		                        		
		                        	
6.Effect of Modified Huangqi Guizhi Wuwutang on Apoptosis-related Bax and Caspase-12 of Sciatic Nerve Cells in Diabetes Rats
Yan ZHANG ; Hongzhu LONG ; Xipeng WANG ; Weifang CAO ; Lili WU ; Tonghua LIU ; Jingxin ZHOU
Chinese Journal of Experimental Traditional Medical Formulae 2023;29(16):58-64
		                        		
		                        			
		                        			ObjectiveTo investigate the effect of modified Huangqi Guizhi Wuwutang (MHGW) on the protein and mRNA expression of B-cell lymphoma-2-associated X protein (Bax) and cysteinyl aspartate specific proteinase-12 (Caspase-12) related to the apoptosis of sciatic nerve cells in diabetes rats to explore the mechanism of MHGW in the treatment of peripheral neuropathy in diabetes. MethodAnimal experiments were conducted. A diabetes model was induced in sixty male sprague-dawley (SD) rats by feeding on a high-sugar and high-fat diet combined with streptozotocin (STZ) intraperitoneal injection. Rats with random blood glucose levels ≥ 16.7 mmol·L-1 for three consecutive days were considered to have successfully developed diabetes. Forty-eight rats that successfully developed diabetes were randomly divided into a model group, an α-lipoic acid group (0.026 8 g·kg-1·d-1), a high-dose MHGW group (2.5 g·kg-1·d-1), and a low-dose MHGW group (1.25 g·kg-1·d-1), with 12 rats in each group. Another 10 rats were assigned to the normal group. Body weight and random blood glucose levels of the rats were monitored. At the end of a 16-week intervention period, the sciatic nerve conduction velocity of the rats was measured using the Key point electromyography collection system. The protein and mRNA expression of Bax and Caspase-12 in the sciatic nerve cells was detected by Western blot analysis and real-time quantitative polymerase chain reaction (Real-time PCR), respectively. ResultCompared with the normal group, the model group showed a significant decrease in body weight (P<0.01) and a significant increase in random blood glucose levels (P<0.01). After a 16-week intervention, compared with the model group, the high-dose MHGW group exhibited a significant increase in body weight (P<0.05), while there were no statistically significant differences in body weight changes among the other treatment groups. Random blood glucose levels significantly decreased in all treatment groups (P<0.01). After 16 weeks of intervention, compared with the normal group, the model group had significantly reduced motor and sensory nerve conduction velocities (P<0.01). Compared with the model group, all treatment groups showed significant increases in motor and sensory nerve conduction velocities (P<0.05, P<0.01). The expression of Bax and Caspase-12 proteins in the sciatic nerve cells was significantly elevated in the model group compared with that in the normal group (P<0.01). In contrast, all treatment groups showed significant reductions in the expression of Bax and Caspase-12 proteins in the sciatic nerve cells as compared with that in the model group (P<0.01). The expression of Bax and Caspase-12 mRNA in the sciatic nerve cells significantly increased in the model group compared with that in the normal group (P<0.01). Compared with the model group, the α-lipoic acid group and the high-dose MHGW group showed significant reductions in the expression of Bax mRNA in the sciatic nerve cells (P<0.05, P<0.01), while the low-dose MHGW group showed a decreasing trend in the expression of Bax mRNA. The expression of Caspase-12 mRNA in the sciatic nerve cells significantly decreased in all treatment groups (P<0.01). ConclusionMHGW may improve and repair sciatic nerve damage in diabetes rats by inhibiting sciatic nerve cell apoptosis. 
		                        		
		                        		
		                        		
		                        	
7.Syndrome Differentiation and Treatment of Obesity from "Orchids to Eliminate Stagnant Qi"
Jingxin ZHOU ; Yizhen LU ; Jie YANG ; Jian JIN ; Juan MIAO ; Yan ZHANG
Chinese Journal of Experimental Traditional Medical Formulae 2023;29(16):72-78
		                        		
		                        			
		                        			Obesity is a chronic, recurrent, and progressive metabolic disorder characterized by the abnormal or excessive accumulation of body fat caused by multiple factors such as genetics, dietary structure, lifestyle and behavior, psychology, environment, and society, leading to an energy surplus. Obesity is a major risk factor that increases the risk of developing various chronic diseases, including type 2 diabetes, hypertension, cardiovascular diseases, stroke, and certain malignancies. The global incidence of obesity is increasing year by year. With the continuous improvement of people's living standards, more than half of adults in China are now overweight or obese, posing a serious threat to people's health and increasing the social and economic burden. It has become a pressing major public health issue that needs to be addressed urgently. The concept of obesity can be traced back to the Huangdi’s Internal Classic (Huang Di Nei Jing), which describes it as "the problems in fat and affluent people are caused by excessive taking of rich food", and suggests that ''frequent intake of rich and greasy foods can produce interior heat. Sweet flavor causes chest fullness. That is why its spleen-Qi flows upwards and changes into consumption-thirst disease. It can be treated by Eupatorii Herba which is used to remove stagnant Qi''. The stagnant qi is caused by the transformation failure of rich and greasy food and wine, so obesity is the disease of stagnant qi. Obesity is caused by indulging in rich and greasy food, wine, spicy and flavorful foods, raw and cold foods, and sweet and greasy foods, or overeating and leading a sedentary lifestyle, staying up late, or experiencing emotional imbalances such as excessive joy, anger, worry, pensiveness, and fear. It can also be caused by congenital abnormalities, leading to improper functioning of the spleen and stomach, dysregulation of the absorption and secretion of the small intestine, and the accumulation of stagnant Qi in the organs and muscles, resulting in a plump physique. The intake of food and drink depends on the functions of the stomach in receiving and decomposing, the small intestine in absorbing and secreting, and the spleen in transforming and transporting. The affected organs in obesity are the spleen, stomach, and small intestine. Orchids, specifically Eupatorii Herba and Lycopi Herba, are aromatic herbs that can regulate the smooth flow of Qi, eliminate stagnation, and cleanse impurities. In a broader sense, any aromatic and pungent substance that can invigorate the spleen, promote clarity, harmonize the stomach, reduce turbidity, and assist in the normal secretion and absorption functions of the small intestine, thereby eliminating excess, is referred to as orchid. Therefore, the treatment principle for obesity is to use ''orchids to eliminate stagnant Qi'', aiming to regulate the functions of the spleen, stomach, and small intestine using aromatic and pungent substances, gradually eliminating excessive dampness, phlegm, turbidity, and heat, and restore the balance of the middle energizer. This way, individuals who are obese can achieve a non-obese state. 
		                        		
		                        		
		                        		
		                        	
8.Improvement of xeroderma and water content of the stratum corneum in children with a moisturizer containing oat kernel oil
Suhua WU ; Kefei ZHOU ; Ming LI ; Jingxin JIANG ; Yizhen ZHANG ; Yan LI ; Linfeng LI
Chinese Journal of Medical Aesthetics and Cosmetology 2023;29(3):218-222
		                        		
		                        			
		                        			Objective:To evaluate the influence of a moisturizer containing oat kernel oil for xeroderma and water content of the stratum corneum in children.Methods:From September to December 2022, 30 children with xeroderma were treated in the Dermatology Department of Tongzhou Maternal and Child Health Hospital of Beijing; 13 were males and 17 were females, and the age was 7.33±2.63 years. This was a single-center self-controlled trial. All children applied the moisturizer on the dry skin of the bilateral limbs two time per day for 14 days, and were followed up at 7 days and 14 days. Efficacy was evaluated according to the water content of the stratum corneum, visual scale, xerosis severity scale (XSS), Specified Symptom Sum Score (SRRC), Visual Analog Scale (VAS) and so on. and side-reactions were recorded.Results:After application of the moisturizer, the median of water content in the stratum corneum was 49.00 (33.83, 87.25), 48.84 (32.58, 100.34) at 7 d and 14 d respectively, showing significant increases compared with that at baseline (median 26.51 (16.00, 47.75) ( Z=-3.075, Z=-2.911, P<0.01). The visual scale, XSS, SRRC and VAS showed that compared with the baseline at 7 d, 14 d, the skin dryness and pruritus scores improved significantly ( Z=-4.424, -4.150, -3.943, -4.400; Z=-4.744, -4.409, -4.260, -4.409, P<0.01). Conclusions:The application of this moisturizer containing oat kernel oil could effectively improve skin dryness and the water content of the stratum corneum without serious adverse reactions.
		                        		
		                        		
		                        		
		                        	
9.Clinical efficacy and safety of ex-vivo liver resection and liver auto-transplantation: a bayesian single-arm Meta-analysis
Yichen FAN ; Manjun DENG ; Jingxin YAN ; Li REN ; Haijiu WANG ; Haining FAN ; Qian LU
Chinese Journal of Hepatobiliary Surgery 2022;28(7):547-554
		                        		
		                        			
		                        			Objective:To evaluate the clinical efficacy and safety of ex vivo liver resection and autotransplantation (ELRA) by using a Bayesian single-arm Meta-analysis.Methods:Databases of PubMed, Embase, Cochrane Library, Web of Science, CNKI, and Wanfang were searched from January 1, 1990 to December 30, 2021 on ELRA studies. The Bayesian one-arm Meta-analysis was performed by using the statistical software of R (V4.1.2) and the Markov chain-Monte Carlo method was used to simulate the posterior distribution. The mortality rate within 30 days after operation, 1-year survival rate, major postoperative complications, R 0 resection rate and other related indexes were analyzed. Results:A total of 20 studies with 436 patients were included. Bayesian single-arm Meta-analysis showed that the 1-year survival rate after ELRA was 83.24% [95% highest posterior density ( HPD): 72.40%-92.05%]. The 1-year survival rates after surgery were 88.66% (95% HPD: 81.52%-94.50%) for patients with hepatic alveolar echinococcosis and 61.29% (95% HPD: 38.53%-93.68%) for patients with hepatic malignancies, respectively. The mortality rate within 30 d after surgery, the incidence of significant postoperative complications, and the R 0 resection rate were 6.96% (95% HPD: 4.47%-10.15%), 27.91% (95% HPD: 19.00%-38.30%), and 99.84% (95% HPD: 37.61%-100.00%), respectively. Renal failure was the most frequent cause of death after ELRA. Conclusion:ELRA is indicated for hepatic malignancies and hepatic alveolar echinococcosis when intrahepatic resection cannot be accomplished in vivo. The greatest benefit is observed in patients with hepatic alveolar echinococcosis, while only some patients with hepatic malignancies can benefit. The indications for ELRA for hepatic malignancies need to be further studied to define the subgroup of patients who can benefit from this operation.
		                        		
		                        		
		                        		
		                        	
10.A broadly neutralizing human monoclonal antibody against the hemagglutinin of avian influenza virus H7N9.
Jingxin LI ; Li ZHANG ; Linlin BAO ; Yuxiao WANG ; Lin QIU ; Jialei HU ; Rong TANG ; Huiyan YU ; Jun SHAN ; Yan LI ; Chuan QIN ; Fengcai ZHU
Chinese Medical Journal 2022;135(7):799-805
		                        		
		                        			BACKGROUND:
		                        			The new emerging avian influenza A H7N9 virus, causing severe human infection with a mortality rate of around 41%. This study aims to provide a novel treatment option for the prevention and control of H7N9.
		                        		
		                        			METHODS:
		                        			H7 hemagglutinin (HA)-specific B cells were isolated from peripheral blood plasma cells of the patients previously infected by H7N9 in Jiangsu Province, China. The human monoclonal antibodies (mAbs) were generated by amplification and cloning of these HA-specific B cells. First, all human mAbs were screened for binding activity by enzyme-linked immunosorbent assay. Then, those mAbs, exhibiting potent affinity to recognize H7 HAs were further evaluated by hemagglutination-inhibiting (HAI) and microneutralization in vitro assays. Finally, the lead mAb candidate was selected and tested against the lethal challenge of the H7N9 virus using murine models.
		                        		
		                        			RESULTS:
		                        			The mAb 6-137 was able to recognize a panel of H7 HAs with high affinity but not HA of other subtypes, including H1N1 and H3N2. The mAb 6-137 can efficiently inhibit the HA activity in the inactivated H7N9 virus and neutralize 100 tissue culture infectious dose 50 (TCID50) of H7N9 virus (influenza A/Nanjing/1/2013) in vitro, with neutralizing activity as low as 78 ng/mL. In addition, the mAb 6-137 protected the mice against the lethal challenge of H7N9 prophylactically and therapeutically.
		                        		
		                        			CONCLUSION
		                        			The mAb 6-137 could be an effective antibody as a prophylactic or therapeutic biological treatment for the H7N9 exposure or infection.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Antibodies, Monoclonal/therapeutic use*
		                        			;
		                        		
		                        			Antibodies, Neutralizing/therapeutic use*
		                        			;
		                        		
		                        			Antibodies, Viral
		                        			;
		                        		
		                        			Hemagglutinins
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Influenza A Virus, H1N1 Subtype
		                        			;
		                        		
		                        			Influenza A Virus, H3N2 Subtype
		                        			;
		                        		
		                        			Influenza A Virus, H7N9 Subtype
		                        			;
		                        		
		                        			Influenza Vaccines
		                        			;
		                        		
		                        			Influenza in Birds
		                        			;
		                        		
		                        			Influenza, Human/prevention & control*
		                        			;
		                        		
		                        			Mice
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail